Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Economics of Cancer Care
ASCO Proposes New Reimbursement Model by Medicare for Cancer Care
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
The American Society of Clinical Oncology (ASCO) has proposed a radical new model for the reimbursement of oncology services under Medicare, with the new paradigm consisting of incentives for oncologists to emphasize quality rather than quantity of care as the greater good to the bottom line.
Read Article
Can FDA Drug Approval Keep Pace with Translational Research?
By
Audrey Andrews
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
With the development of targeted therapies, there has been a clear evolution in the pathway to the approval of drugs by the US Food and Drug Administration (FDA), and a rapid approval of a drug after phase 1 clinical trials, which show definitive proof of activity and safety, and “breakthrough” designation, are now possible.
Read Article
PET Use for NSCLC Management Has Altered Resource Utilization, Increased Cost
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Atlanta, GA—The adoption of positron emission tomography (PET) imaging for the management of patients with non–small-cell lung cancer (NSCLC) has had a mixed impact on clinical and economic outcomes, according to findings from a large retrospective cohort study.
Read Article
Panel Recommends Major Changes for Cutting Down Cancer Overdiagnosis and Overtreatment
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
For the past 30 years, awareness and screening have led to an emphasis on the early diagnosis of cancer. The goals were to get screened and to catch cancer early to reduce the rate of late-stage disease and to decrease cancer mortality.
Read Article
Cost-Effective Strategy for Early NSCLC Hinges on Operability of the Disease
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Surgery and stereotactic body radiotherapy (SBRT) proved cost-effective strategies for stage I non–small-cell lung cancer (NSCLC) when applied to specific patient populations, according to a study reported at the 2013 American Society for Radiation Oncology meeting.
Read Article
Rising Costs of Cancer Survivorship a Growing Concern
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
,
Survivorship
November 2013, Vol 4, No 9
Survival is not cheap. In fact, according to the results of a new study, cancer survivors have ongoing annual medical expenditures averaging $17,000 per patient in the first year after diagnosis, or $6400 per patient at least 1 year postdiagnosis (Guy GP Jr, et al. J Clin Oncol. 2013;31:3749-3757).
Read Article
Health Disparities in Oncology: Western Europe Spends More, Achieves Better Patient Survival Outcomes than Eastern Europe
By
Audrey Andrews
Disparities in Oncology
,
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Amsterdam, The Netherlands—The more a European Union (EU) country spends on health, the fewer the cancer-related deaths occur in that country, and there is a great disparity between Western and Eastern EU countries, according to research presented at the 2013 European Cancer Congress.
Read Article
Costs to Medicare Nearly Twice as High for Hospital Outpatient versus Community-Based Oncology Services
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
October 2013, Vol 4, No 8
A new analysis of Medicare claims between 2009 and 2011 has revealed that patients with cancer receiving chemotherapy in hospital outpatient settings are billed at rates that are 25% to 47% higher than for equivalent oncology services rendered at community-based physicians’ offices.
Read Article
IOM Cites Looming Cancer Care Crisis, Recommends Course-Correcting Strategies
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
October 2013, Vol 4, No 8
An evolving crisis in cancer care will reach a critical mass over the next 15 to 20 years without a transition to a more patient-centered, evidence-based delivery system, warn the authors of a report from the Institute of Medicine (IOM).
Read Article
Routine Surveillance CT Costly, Unnecessary in Lymphoma in Remission
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
Chicago, IL—Routine surveillance imaging is of little value in patients with diffuse large B-cell lymphoma (DLBCL) or classical Hodgkin lymphoma who are in remission, researchers from 2 institutions reported.
Read Article
Page 6 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma